Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The Company believes that such higher doses may enhance the potential of VAL-083 to impact a patent's tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.
  • DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.
  • DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.
  • DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the Company with additional non-dilutive capital, which the Company believes will be sufficient to fund current operations through at least the end of December 2015. 
  • Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, "We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our ove
    '/>"/>

    SOURCE DelMar Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
    (Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
    (Date:8/28/2015)... , August 28, 2015 The ... reach USD 49.12 billion by 2020, growing at a ... a new report by Grand View Research, Inc. Monitoring ... of 49.7% from 2014 to 2020.      ... population along with rising incidences of chronic diseases such ...
    Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
    ...  Results from the combined analysis of two European ... 3rd European Lung Cancer Conference in Geneva, Switzerland. ... samples from advanced non-squamous non-small cell lung cancer ... plus erlotinib.  Results showed that the VeriStrat test ...
    ... (NASDAQ: STAA ), the leading developer, manufacturer and ... that the total number of its Visian® ICL implants in ... have been the Visian Toric ICL which is approved in ... of the U.S. The Company will highlight the benefits of ...
    Cached Medicine Technology:VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 2STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 4STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 5
    (Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the ... has added yet another accolade to its cadre of widespread support—an official letter of ... the help of the medical community and the University of Illinois at Chicago’s Department ...
    (Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... “ Frequentz ... look at the latest and coolest applications on the market for iOS, Android, and ... and shared with viewers how this software allows businesses to track product movement from ...
    (Date:8/28/2015)... ... August 28, 2015 , ... The ... honoring military veterans leading in business. Mr. Troy Mizell, Chairman of the ... inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, ...
    (Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic ... the first and only nonsurgical product approved by the Food and Drug Administration to ... and Dr. William Koenig are among the premier cosmetic surgeons in ...
    (Date:8/28/2015)... La Mirada, Ca (PRWEB) , ... August 28, ... ... are now administering medical evaluations for those seeking to go deep sea diving. ... pressure, possible oxygen toxicity, and decompression sickness; for these reasons, it is vital ...
    Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2
    ... William V. Corr, Executive Director, Campaign for,Tobacco-Free Kids, ... a,statement of William V. Corr, Executive Director, Campaign ... fall further behind in protecting,workers and the public ... two,more states - neighboring Maryland and Minnesota - ...
    ... Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... the United States Department of Justice ("DOJ"),and the ... District of,Massachusetts resolving the previously disclosed investigations that ... and sales and,marketing activities. The company announced in ...
    ... A market-based program is improving air quality, agency claims ... nitrogen oxides (NOx) from power plants, cars and other ... -- making for less ozone and therefore less smog ... to the NOx Budget Trading Program annual report from ...
    ... PARK, Ill., Sept. 28 Abbott (NYSE:,ABT) will announce ... before the market opens. The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
    ... A Competitive Intelligence,executive once said: "CI is like ... you realize you need it is when it is ... in Competitive Intelligence or have been a,client for such ... on an organization,s position in the,marketplace. By delivering high-impact ...
    ... have suffered a stroke and lessen their chances of deteriorating, ... , Stroke is the second leading cause of death in ... in adults. Six months after a stroke approximately half ... out everyday tasks such as eating, dressing and going to ...
    Cached Medicine News:Health News:Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit 2Health News:Less Smog Now in Eastern U.S.: EPA 2Health News:Uncover Key Competitive Intelligence Insights in Webinars Hosted by Best Practices 2